Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus chemotherapy with or without Anlotinib in advanced ESCC
NCT05214222Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective Response Rate at 2 years. Started Sep 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05214222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214222.